| Year |
Citation |
Score |
| 2020 |
Guo CC, Bondaruk J, Yao H, Wang Z, Zhang L, Lee S, Lee JG, Cogdell D, Zhang M, Yang G, Dadhania V, Choi W, Wei P, Gao J, Theodorescu D, et al. Assessment of Luminal and Basal Phenotypes in Bladder Cancer. Scientific Reports. 10: 9743. PMID 32546765 DOI: 10.1038/S41598-020-66747-7 |
0.351 |
|
| 2020 |
Yang G, Bondaruk J, Cogdell D, Wang Z, Lee S, Lee JG, Zhang S, Choi W, Wang Y, Liang Y, Wang G, Wang Y, Yao H, Dadhania V, Gao J, ... ... Theodorescu D, et al. Urothelial-to-Neural Plasticity Drives Progression to Small Cell Bladder Cancer. Iscience. 23: 101201. PMID 32521509 DOI: 10.1016/J.Isci.2020.101201 |
0.313 |
|
| 2018 |
Goodspeed A, Jean A, Theodorescu D, Costello JC. A Gene Expression Signature Predicts Bladder Cancer Cell Line Sensitivity to EGFR Inhibition. Bladder Cancer (Amsterdam, Netherlands). 4: 269-282. PMID 30112438 DOI: 10.3233/BLC-170161 |
0.361 |
|
| 2018 |
Fantini D, Glaser AP, Rimar KJ, Wang Y, Schipma M, Varghese N, Rademaker A, Behdad A, Yellapa A, Yu Y, Sze CC, Wang L, Zhao Z, Crawford SE, Hu D, ... ... Theodorescu D, et al. A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer. Oncogene. PMID 29367767 DOI: 10.1038/S41388-017-0099-6 |
0.315 |
|
| 2017 |
Felsenstein KM, Theodorescu D. Precision medicine for urothelial bladder cancer: update on tumour genomics and immunotherapy. Nature Reviews. Urology. PMID 29133939 DOI: 10.1038/Nrurol.2017.179 |
0.342 |
|
| 2017 |
Zuiverloon TC, Theodorescu D. Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer. Pharmacogenomics. PMID 28745580 DOI: 10.2217/Pgs-2017-0055 |
0.319 |
|
| 2016 |
Nickerson ML, Witte N, Im KM, Turan S, Owens C, Misner K, Tsang SX, Cai Z, Wu S, Dean M, Costello JC, Theodorescu D. Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response. Oncogene. PMID 27270441 DOI: 10.1038/Onc.2016.172 |
0.347 |
|
| 2016 |
Frantzi M, Van Kessel KE, Zwarthoff EC, Marquez M, Rava M, Malats N, Merseburger AS, Katafigiotis I, Stravodimos K, Mullen W, Zoidakis J, Makridakis M, Pejchinovski M, Critselis E, Lichtinghagen R, ... ... Theodorescu D, et al. Development and validation of urine-based peptide biomarker panels for detecting bladder cancer in a multi-center study. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27026199 DOI: 10.1158/1078-0432.Ccr-15-2715 |
0.321 |
|
| 2015 |
Dancik GM, Theodorescu D. The Prognostic Value of Cell Cycle Gene Expression Signatures in Muscle Invasive, High-Grade Bladder Cancer. Bladder Cancer (Amsterdam, Netherlands). 1: 45-63. PMID 30561442 DOI: 10.3233/BLC-150012 |
0.367 |
|
| 2015 |
Guin S, Ru Y, Agarwal N, Lew CR, Owens C, Comi GP, Theodorescu D. Loss of Glycogen Debranching Enzyme AGL Drives Bladder Tumor Growth via Induction of Hyaluronic Acid Synthesis. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26490312 DOI: 10.1158/1078-0432.Ccr-15-1706 |
0.304 |
|
| 2015 |
Hensel J, Duex JE, Owens C, Dancik GM, Edwards MG, Frierson HF, Theodorescu D. Patient mutation directed shRNA screen uncovers novel bladder tumor growth suppressors. Molecular Cancer Research : McR. PMID 26078295 DOI: 10.1158/1541-7786.Mcr-15-0130 |
0.394 |
|
| 2015 |
Ritterson Lew C, Guin S, Theodorescu D. Targeting glycogen metabolism in bladder cancer. Nature Reviews. Urology. 12: 383-91. PMID 26032551 DOI: 10.1038/Nrurol.2015.111 |
0.322 |
|
| 2015 |
Earl J, Rico D, Carrillo-de-Santa-Pau E, Rodríguez-Santiago B, Méndez-Pertuz M, Auer H, Gómez G, Grossman HB, Pisano DG, Schulz WA, Pérez-Jurado LA, Carrato A, Theodorescu D, Chanock S, Valencia A, et al. The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies. Bmc Genomics. 16: 403. PMID 25997541 DOI: 10.1186/S12864-015-1450-3 |
0.337 |
|
| 2015 |
Apolo AB, Vogelzang NJ, Theodorescu D. New and promising strategies in the management of bladder cancer. American Society of Clinical Oncology Educational Book / Asco. American Society of Clinical Oncology. Meeting. 105-12. PMID 25993148 DOI: 10.14694/EdBook_AM.2015.35.105 |
0.413 |
|
| 2015 |
Borah S, Xi L, Zaug AJ, Powell NM, Dancik GM, Cohen SB, Costello JC, Theodorescu D, Cech TR. Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science (New York, N.Y.). 347: 1006-10. PMID 25722414 DOI: 10.1126/Science.1260200 |
0.325 |
|
| 2015 |
Griner EM, Dancik GM, Costello JC, Owens C, Guin S, Edwards MG, Brautigan DL, Theodorescu D. RhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer. Molecular Cancer Research : McR. 13: 483-92. PMID 25516960 DOI: 10.1158/1541-7786.Mcr-14-0420 |
0.318 |
|
| 2015 |
Lew CR, Guin S, Theodorescu D. Targeting glycogen metabolism in bladder cancer Nature Reviews Urology. 12: 383-391. DOI: 10.1038/nrurol.2015.111 |
0.322 |
|
| 2014 |
Guin S, Pollard C, Ru Y, Ritterson Lew C, Duex JE, Dancik G, Owens C, Spencer A, Knight S, Holemon H, Gupta S, Hansel D, Hellerstein M, Lorkiewicz P, Lane AN, ... Theodorescu D, et al. Role in tumor growth of a glycogen debranching enzyme lost in glycogen storage disease. Journal of the National Cancer Institute. 106. PMID 24700805 DOI: 10.1093/Jnci/Dju062 |
0.585 |
|
| 2014 |
Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM, Antonarakis ES, Azad NS, Bardelli A, Brem H, Cameron JL, ... ... Theodorescu D, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Science Translational Medicine. 6: 224ra24. PMID 24553385 DOI: 10.1126/Scitranslmed.3007094 |
0.387 |
|
| 2014 |
Dancik GM, Theodorescu D. Pharmacogenomics in bladder cancer. Urologic Oncology. 32: 16-22. PMID 24360659 DOI: 10.1016/J.Urolonc.2013.09.007 |
0.303 |
|
| 2014 |
Dancik GM, Owens CR, Iczkowski KA, Theodorescu D. A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors. Stem Cells (Dayton, Ohio). 32: 974-82. PMID 24357085 DOI: 10.1002/Stem.1625 |
0.369 |
|
| 2013 |
Guo G, Sun X, Chen C, Wu S, Huang P, Li Z, Dean M, Huang Y, Jia W, Zhou Q, Tang A, Yang Z, Li X, Song P, Zhao X, ... ... Theodorescu D, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nature Genetics. 45: 1459-63. PMID 24121792 DOI: 10.1038/Ng.2798 |
0.328 |
|
| 2013 |
Solomon DA, Kim JS, Bondaruk J, Shariat SF, Wang ZF, Elkahloun AG, Ozawa T, Gerard J, Zhuang D, Zhang S, Navai N, Siefker-Radtke A, Phillips JJ, Robinson BD, Rubin MA, ... ... Theodorescu D, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nature Genetics. 45: 1428-30. PMID 24121789 DOI: 10.1038/Ng.2800 |
0.33 |
|
| 2013 |
Wang H, Ru Y, Sanchez-Carbayo M, Wang X, Kieft JS, Theodorescu D. Translation initiation factor eIF3b expression in human cancer and its role in tumor growth and lung colonization. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 2850-60. PMID 23575475 DOI: 10.1158/1078-0432.Ccr-12-3084 |
0.34 |
|
| 2013 |
Said N, Frierson HF, Sanchez-Carbayo M, Brekken RA, Theodorescu D. Loss of SPARC in bladder cancer enhances carcinogenesis and progression. The Journal of Clinical Investigation. 123: 751-66. PMID 23321672 DOI: 10.1172/Jci64782 |
0.366 |
|
| 2013 |
Grau L, Luque-Garcia JL, González-Peramato P, Theodorescu D, Palou J, Fernandez-Gomez JM, Sánchez-Carbayo M. A quantitative proteomic analysis uncovers the relevance of CUL3 in bladder cancer aggressiveness. Plos One. 8: e53328. PMID 23308193 DOI: 10.1371/Journal.Pone.0053328 |
0.346 |
|
| 2012 |
Said N, Theodorescu D. RhoGDI2 suppresses bladder cancer metastasis via reduction of inflammation in the tumor microenvironment. Oncoimmunology. 1: 1175-1177. PMID 23170270 DOI: 10.4161/Onci.20594 |
0.329 |
|
| 2012 |
Said N, Theodorescu D. Permissive role of endothelin receptors in tumor metastasis. Life Sciences. 91: 522-7. PMID 22846215 DOI: 10.1016/J.Lfs.2012.03.040 |
0.303 |
|
| 2012 |
Griner EM, Theodorescu D. The faces and friends of RhoGDI2. Cancer Metastasis Reviews. 31: 519-28. PMID 22718398 DOI: 10.1007/S10555-012-9376-6 |
0.328 |
|
| 2012 |
DeGraff DJ, Clark PE, Cates JM, Yamashita H, Robinson VL, Yu X, Smolkin ME, Chang SS, Cookson MS, Herrick MK, Shariat SF, Steinberg GD, Frierson HF, Wu XR, Theodorescu D, et al. Loss of the urothelial differentiation marker FOXA1 is associated with high grade, late stage bladder cancer and increased tumor proliferation. Plos One. 7: e36669. PMID 22590586 DOI: 10.1371/Journal.Pone.0036669 |
0.383 |
|
| 2012 |
Smith SC, Baras AS, Owens CR, Dancik G, Theodorescu D. Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer. Cancer Research. 72: 3480-91. PMID 22586063 DOI: 10.1158/0008-5472.Can-11-3966 |
0.405 |
|
| 2012 |
Said N, Sanchez-Carbayo M, Smith SC, Theodorescu D. RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. The Journal of Clinical Investigation. 122: 1503-18. PMID 22406535 DOI: 10.1172/Jci61392 |
0.368 |
|
| 2011 |
Williams PD, Owens CR, Dziegielewski J, Moskaluk CA, Read PW, Larner JM, Story MD, Brock WA, Amundson SA, Lee JK, Theodorescu D. Cyclophilin B expression is associated with in vitro radioresistance and clinical outcome after radiotherapy. Neoplasia (New York, N.Y.). 13: 1122-31. PMID 22241958 DOI: 10.1593/Neo.111398 |
0.337 |
|
| 2011 |
Dancik GM, Ru Y, Owens CR, Theodorescu D. A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers. Cancer Research. 71: 7398-409. PMID 22012889 DOI: 10.1158/0008-5472.Can-11-2427 |
0.316 |
|
| 2011 |
Dancik G, Aisner D, Theodorescu D. A 20 gene model for predicting nodal involvement in bladder cancer patients with muscle invasive tumors. Plos Currents. 3: RRN1248. PMID 21858252 DOI: 10.1371/Currents.Rrn1248 |
0.329 |
|
| 2011 |
Gui Y, Guo G, Huang Y, Hu X, Tang A, Gao S, Wu R, Chen C, Li X, Zhou L, He M, Li Z, Sun X, Jia W, Chen J, ... ... Theodorescu D, et al. Frequent mutations of chromatin remodeling genes in transitional cell carcinoma of the bladder. Nature Genetics. 43: 875-8. PMID 21822268 DOI: 10.1038/Ng.907 |
0.335 |
|
| 2011 |
Ru Y, Dancik GM, Theodorescu D. Biomarkers for prognosis and treatment selection in advanced bladder cancer patients. Current Opinion in Urology. 21: 420-7. PMID 21814055 DOI: 10.1097/Mou.0B013E32834956D6 |
0.336 |
|
| 2011 |
Nitz MD, Harding MA, Smith SC, Thomas S, Theodorescu D. RREB1 transcription factor splice variants in urologic cancer. The American Journal of Pathology. 179: 477-86. PMID 21703425 DOI: 10.1016/J.Ajpath.2011.03.038 |
0.342 |
|
| 2011 |
Smith SC, Havaleshko DM, Moon K, Baras AS, Lee J, Bekiranov S, Burke DJ, Theodorescu D. Use of yeast chemigenomics and COXEN informatics in preclinical evaluation of anticancer agents. Neoplasia (New York, N.Y.). 13: 72-80. PMID 21253455 DOI: 10.1593/Neo.101214 |
0.319 |
|
| 2011 |
Said N, Smith S, Sanchez-Carbayo M, Theodorescu D. Tumor endothelin-1 enhances metastatic colonization of the lung in mouse xenograft models of bladder cancer. The Journal of Clinical Investigation. 121: 132-47. PMID 21183790 DOI: 10.1172/Jci42912 |
0.308 |
|
| 2011 |
Thomas S, Overdevest JB, Nitz MD, Williams PD, Owens CR, Sanchez-Carbayo M, Frierson HF, Schwartz MA, Theodorescu D. Src and caveolin-1 reciprocally regulate metastasis via a common downstream signaling pathway in bladder cancer. Cancer Research. 71: 832-41. PMID 21148751 DOI: 10.1158/0008-5472.Can-10-0730 |
0.327 |
|
| 2011 |
Ehdaie B, Theodorescu D. Molecular markers in transitional cell carcinoma of the bladder: New insights into mechanisms and prognosis. Indian Journal of Urology : Iju : Journal of the Urological Society of India. 24: 61-7. PMID 19468362 DOI: 10.4103/0970-1591.38606 |
0.347 |
|
| 2010 |
Harding MA, Theodorescu D. RhoGDI signaling provides targets for cancer therapy. European Journal of Cancer (Oxford, England : 1990). 46: 1252-9. PMID 20347589 DOI: 10.1016/J.Ejca.2010.02.025 |
0.319 |
|
| 2010 |
Pollard C, Smith SC, Theodorescu D. Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC). Expert Reviews in Molecular Medicine. 12: e10. PMID 20334706 DOI: 10.1017/S1462399410001407 |
0.567 |
|
| 2010 |
Smith SC, Baras AS, Lee JK, Theodorescu D. The COXEN principle: translating signatures of in vitro chemosensitivity into tools for clinical outcome prediction and drug discovery in cancer. Cancer Research. 70: 1753-8. PMID 20160033 DOI: 10.1158/0008-5472.Can-09-3562 |
0.326 |
|
| 2009 |
Ehdaie B, Smith SC, Theodorescu D. Personalized medicine in advanced urothelial cancer: when to treat, how to treat and who to treat. Canadian Urological Association Journal = Journal De L'Association Des Urologues Du Canada. 3: S232-6. PMID 20019992 DOI: 10.5489/Cuaj.1204 |
0.347 |
|
| 2009 |
Said N, Theodorescu D. Pathways of metastasis suppression in bladder cancer. Cancer Metastasis Reviews. 28: 327-33. PMID 20013033 DOI: 10.1007/S10555-009-9197-4 |
0.376 |
|
| 2009 |
Hussain MH, Wood DP, Bajorin DF, Bochner BH, Dreicer R, Lamm DL, O'Donnell MA, Siefker-Radtke AO, Theodorescu D, Dinney CP. Bladder cancer: narrowing the gap between evidence and practice. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5680-4. PMID 19858384 DOI: 10.1200/Jco.2009.23.6901 |
0.31 |
|
| 2009 |
Williams PD, Cheon S, Havaleshko DM, Jeong H, Cheng F, Theodorescu D, Lee JK. Concordant gene expression signatures predict clinical outcomes of cancer patients undergoing systemic therapy. Cancer Research. 69: 8302-9. PMID 19843853 DOI: 10.1158/0008-5472.Can-09-0798 |
0.334 |
|
| 2009 |
Pollard C, Nitz M, Baras A, Williams P, Moskaluk C, Theodorescu D. Genoproteomic mining of urothelial cancer suggests {gamma}-glutamyl hydrolase and diazepam-binding inhibitor as putative urinary markers of outcome after chemotherapy. The American Journal of Pathology. 175: 1824-30. PMID 19815704 DOI: 10.2353/Ajpath.2009.090155 |
0.564 |
|
| 2009 |
Slack-Davis JK, Hershey ED, Theodorescu D, Frierson HF, Parsons JT. Differential requirement for focal adhesion kinase signaling in cancer progression in the transgenic adenocarcinoma of mouse prostate model Molecular Cancer Therapeutics. 8: 2470-2477. PMID 19671741 DOI: 10.1158/1535-7163.Mct-09-0262 |
0.339 |
|
| 2009 |
Wu Y, Moissoglu K, Wang H, Wang X, Frierson HF, Schwartz MA, Theodorescu D. Src phosphorylation of RhoGDI2 regulates its metastasis suppressor function. Proceedings of the National Academy of Sciences of the United States of America. 106: 5807-12. PMID 19321744 DOI: 10.1073/Pnas.0810094106 |
0.343 |
|
| 2009 |
Smith SC, Nicholson B, Nitz M, Frierson HF, Smolkin M, Hampton G, El-Rifai W, Theodorescu D. Profiling bladder cancer organ site-specific metastasis identifies LAMC2 as a novel biomarker of hematogenous dissemination. The American Journal of Pathology. 174: 371-9. PMID 19147813 DOI: 10.2353/ajpath.2009.080538 |
0.339 |
|
| 2009 |
Smith SC, Theodorescu D. The Ral GTPase pathway in metastatic bladder cancer: key mediator and therapeutic target. Urologic Oncology. 27: 42-7. PMID 19111797 DOI: 10.1016/j.urolonc.2008.04.012 |
0.394 |
|
| 2008 |
Wu Y, Siadaty MS, Berens ME, Hampton GM, Theodorescu D. Overlapping gene expression profiles of cell migration and tumor invasion in human bladder cancer identify metallothionein 1E and nicotinamide N-methyltransferase as novel regulators of cell migration. Oncogene. 27: 6679-89. PMID 18724390 DOI: 10.1038/Onc.2008.264 |
0.316 |
|
| 2008 |
Williams PD, Lee JK, Theodorescu D. Molecular credentialing of rodent bladder carcinogenesis models. Neoplasia (New York, N.Y.). 10: 838-46. PMID 18670642 DOI: 10.1593/Neo.08432 |
0.363 |
|
| 2008 |
Ehdaie B, Theodorescu D. Predicting tumor outcomes in urothelial bladder carcinoma: turning pathways into clinical biomarkers of prognosis. Expert Review of Anticancer Therapy. 8: 1103-10. PMID 18588455 DOI: 10.1586/14737140.8.7.1103 |
0.4 |
|
| 2008 |
Nitz MD, Harding MA, Theodorescu D. Invasion and metastasis models for studying RhoGDI2 in bladder cancer. Methods in Enzymology. 439: 219-33. PMID 18374168 DOI: 10.1016/S0076-6879(07)00417-X |
0.346 |
|
| 2008 |
Smalley DM, Sheman NE, Nelson K, Theodorescu D. Isolation and identification of potential urinary microparticle biomarkers of bladder cancer. Journal of Proteome Research. 7: 2088-96. PMID 18373357 DOI: 10.1021/Pr700775X |
0.302 |
|
| 2008 |
Steeg PS, Theodorescu D. Metastasis: a therapeutic target for cancer. Nature Clinical Practice. Oncology. 5: 206-19. PMID 18253104 DOI: 10.1038/Ncponc1066 |
0.332 |
|
| 2007 |
Harding MA, Theodorescu D. RhoGDI2: a new metastasis suppressor gene: discovery and clinical translation. Urologic Oncology. 25: 401-6. PMID 17826660 DOI: 10.1016/J.Urolonc.2007.05.006 |
0.311 |
|
| 2007 |
Havaleshko DM, Cho H, Conaway M, Owens CR, Hampton G, Lee JK, Theodorescu D. Prediction of drug combination chemosensitivity in human bladder cancer. Molecular Cancer Therapeutics. 6: 578-86. PMID 17308055 DOI: 10.1158/1535-7163.Mct-06-0497 |
0.303 |
|
| 2007 |
Herlevsen M, Oxford G, Ptak C, Shabanowitz J, Hunt DF, Conaway M, Theodorescu D. A novel model to identify interaction partners of the PTEN tumor suppressor gene in human bladder cancer. Biochemical and Biophysical Research Communications. 352: 549-55. PMID 17126809 DOI: 10.1016/J.Bbrc.2006.11.067 |
0.385 |
|
| 2007 |
Thomas CY, Theodorescu D. Molecular markers of prognosis and novel therapeutic strategies for urothelial cell carcinomas. World Journal of Urology. 24: 565-78. PMID 17063322 DOI: 10.1007/S00345-006-0119-6 |
0.435 |
|
| 2007 |
Wu Y, McRoberts K, Berr SS, Frierson HF, Conaway M, Theodorescu D. Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia Oncogene. 26: 765-773. PMID 16878152 DOI: 10.1038/Sj.Onc.1209835 |
0.355 |
|
| 2006 |
Theodorescu D, Wittke S, Ross MM, Walden M, Conaway M, Just I, Mischak H, Frierson HF. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. The Lancet. Oncology. 7: 230-40. PMID 16510332 DOI: 10.1016/S1470-2045(06)70584-8 |
0.327 |
|
| 2005 |
Titus B, Frierson HF, Conaway M, Ching K, Guise T, Chirgwin J, Hampton G, Theodorescu D. Endothelin axis is a target of the lung metastasis suppressor gene RhoGDI2. Cancer Research. 65: 7320-7. PMID 16103083 DOI: 10.1158/0008-5472.Can-05-1403 |
0.303 |
|
| 2004 |
Nicholson BE, Frierson HF, Conaway MR, Seraj JM, Harding MA, Hampton GM, Theodorescu D. Profiling the evolution of human metastatic bladder cancer. Cancer Research. 64: 7813-21. PMID 15520187 DOI: 10.1158/0008-5472.Can-04-0826 |
0.33 |
|
| 2004 |
Gildea JJ, Herlevsen M, Harding MA, Gulding KM, Moskaluk CA, Frierson HF, Theodorescu D. PTEN can inhibit in vitro organotypic and in vivo orthotopic invasion of human bladder cancer cells even in the absence of its lipid phosphatase activity. Oncogene. 23: 6788-97. PMID 15273733 DOI: 10.1038/Sj.Onc.1207599 |
0.327 |
|
| 2004 |
Theodorescu D, Sapinoso LM, Conaway MR, Oxford G, Hampton GM, Frierson HF. Reduced expression of metastasis suppressor RhoGDI2 is associated with decreased survival for patients with bladder cancer Clinical Cancer Research. 10: 3800-3806. PMID 15173088 DOI: 10.1158/1078-0432.Ccr-03-0653 |
0.398 |
|
| 2003 |
Oxford G, Theodorescu D. The role of Ras superfamily proteins in bladder cancer progression. The Journal of Urology. 170: 1987-93. PMID 14532839 DOI: 10.1097/01.Ju.0000088670.02905.78 |
0.404 |
|
| 2003 |
Theodorescu D. Molecular pathogenesis of urothelial bladder cancer. Histology and Histopathology. 18: 259-74. PMID 12507305 DOI: 10.14670/HH-18.259 |
0.367 |
|
| 1999 |
Harding MA, Theodorescu D. Prognostic markers in localized prostate cancer: from microscopes to molecules. Cancer Metastasis Reviews. 17: 429-37. PMID 10453287 DOI: 10.1023/A:1006137721823 |
0.323 |
|
| 1998 |
Theodorescu D, Laderoute KR, Calaoagan JM, Guilding KM. Inhibition of human bladder cancer cell motility by genistein is dependent on epidermal growth factor receptor but not p21ras gene expression. International Journal of Cancer. 78: 775-82. PMID 9833772 DOI: 10.1002/(Sici)1097-0215(19981209)78:6<775::Aid-Ijc16>3.0.Co;2-G |
0.367 |
|
| 1997 |
Theodorescu D, Broder SR, Boyd JC, Mills SE, Frierson HF. p53, bcl-2 and retinoblastoma proteins as long-term prognostic markers in localized carcinoma of the prostate. The Journal of Urology. 158: 131-7. PMID 9186339 DOI: 10.1097/00005392-199707000-00040 |
0.323 |
|
| 1997 |
Harding M, Theodorescu D. Molecular markers: their role as prognostic indicators for bladder cancer Current Opinion in Urology. 7: 282-286. DOI: 10.1097/00042307-199709000-00008 |
0.329 |
|
| 1991 |
Theodorescu D, Cornil I, Fernandez BJ, Kerbel RS. Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. Proceedings of the National Academy of Sciences of the United States of America. 87: 9047-51. PMID 2247480 DOI: 10.1073/Pnas.87.22.9047 |
0.369 |
|
| Show low-probability matches. |